Here are Insider's biggest healthcare stories for November
Welcome to a special Black Friday edition of
- A rushed Teladoc and Livongo merger led to a wave of senior exits;
- Getting patents could make or break psychedelic companies;
- One of Moderna's top scientists on why he thinks gene editing is the future of the company.
Sign up today and become an Insider for our lowest annual subscription rate ever — just $38 for full access to everything we offer.
Teladoc acquired Livongo to recreate healthcare. A rushed union, a wave of senior exits, and sky-high expectations are testing the $14 billion bet.
- It's been one year since
Teladoc's megamerger with the chronic-care company Livongo.
- The goal is to build one app that covers primary care, chronic care, and other services.
- Teladoc has faced internal and external pressure, and more than 110 Livongo employees have left.
- The nascent psychedelics industry is headed toward a reckoning.
- Experts say a slew of patent disclosures could determine the winners and losers of the space.
- That may also set off a wave of M&A as companies vie to win market share.
The scientist who helped Moderna become a vaccine powerhouse tells us why he thinks gene editing is the future for the $91 billion biotech
- Eric Huang, who persuaded
Modernato make vaccines, is now steering the biotech into gene editing.
- Huang is the chief scientific officer of Moderna Genomics, a new unit in the $91 billion company.
- Huang intends to strike deals with smaller biotechs while building up Moderna's internal research.
In case you missed it:
- How Amy Abernethy is rejiggering one of Verily's biggest bets to change clinical research and propel the Google spin-off into the future
- See the 16-slide presentation a former Uber exec used to raise $25 million to tackle the growing in-home care market
- The health-insurance giant UnitedHealth is sending more members to in-house doctors in a bid to lower costs and increase profits
- Cathie Wood's Ark has scooped up shares of Ginkgo and Zymergen as their stocks fell. Here's why she's betting synthetic biology will be the next wave of drug development.
- Akasa Air takes to the skies, flagged off by Civil aviation minister
- As FIIs come back, India's forex reserves rise by $2.4 bn
- Markets to keep a close watch on US and Indian inflation data
- Demand for tablets drops as online schooling ends
- Reliance Industries will be hosting its 45th AGM this month — all your need to know